ISRCTN ISRCTN19554893
DOI https://doi.org/10.1186/ISRCTN19554893
Integrated Research Application System (IRAS) 1013719
Sponsor Neurocrine Switzerland GmbH
Funder Neurocrine Switzerland GmbH
Submission date
18/08/2026
Registration date
18/08/2026
Last edited
18/08/2026
Recruitment status
Recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Dr Litza McKenzie
Principal investigator

Mere Way, Ruddington Fields, Ruddington
Nottingham
NG11 6JS
United Kingdom

Phone +44 (0)3303031000
Email recruitment@weneedyou.co.uk
Neurocrine Switzerland GmbH Study Doctor
Public, Scientific

Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
Allschwil
4123
Switzerland

Phone +359 887580697
Email Centermedinfo@neurocrine.com

Study information

Primary study designInterventional
AllocationNon-randomized controlled trial
MaskingOpen (masking not used)
ControlActive
AssignmentThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
PurposePhase I trial in healthy volunteers
Scientific titleDeferred registration: Quotient Sciences Code: QSC303849 [Full scientific title to be added on or before the deferral expiry date]
Study objectives This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)

Submitted 19/06/2026, London Brent Research Ethics Committee (REC) (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048128; brent.rec@hra.nhs.uk), ref: 26/LO/0239

Health condition(s) or problem(s) studiedHealthy volunteers
InterventionThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Primary outcome measure(s)
  1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)
Completion date06/02/2027

Eligibility

Participant type(s)
Age groupAdult
Lower age limit18 Years
Upper age limit55 Years
SexAll
Target sample size at registration16
Key inclusion criteriaThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteriaThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment19/08/2026
Date of final enrolment06/02/2027

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Quotient Sciences
Mere Way
Ruddington Fields
Ruddington
Nottingham
NG11 6JS
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

18/08/2026: Study's existence confirmed by the MHRA.